Biogen (BIIB) tops earnings expectations, reveals workforce reduction
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/7/2026
- Wall St set for best week since April as payrolls surprise eases rate-hike jitters
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Oil gains on US jobs report, worries over peace talks
- Atlassian results seen as 'game changer' for AI kills software worries
- The Trade Desk hit by Wall St downgrades after disappointing Q2 results, outlook
- Trump held multiple undisclosed calls with Fed Chair Warsh, reports say
- Stocks close lower as investors eye Mideast talks, earnings
- Citi says buy the pullback in memory stocks as upcycle is still in early innings
- Apollo to acquire easyJet for £5.7B in cash deal
- The Trade Desk Inc. (TTD) Tops Q2 EPS by 16c, Misses on Revenue; Offers Weak Q3 Revenue Guidance
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
GE, General Motors, Verizon rise premarket; Goldman Sachs, Dow fall
July 25, 2023 7:50 AM EDTInvesting.com -- U.S. futures edged higher Tuesday, as investors digest a deluge of corporate earnings ahead of a key Federal Reserve meeting.
Here are some of the biggest premarket U.S. stock movers today:
General Motors (NYSE: GM) stock rose 2% after the auto giant lifted its full-year... More
Biogen announces job cuts, turns focus to Alzheimer's drug launch
July 25, 2023 7:04 AM EDTBy Manas Mishra and Mariam Sunny
(Reuters) -Biogen Inc said on Tuesday it expects to slash about 1,000 jobs, or 11% of its workforce, in a fresh round of cost-cutting as it looks to the launch of a new Alzheimer's drug to help it return to growth.
The company said its costs are elevated compared to rivals and that it would focus on higher-growth products such as the recently approved Alzheimer's drug Leqembi, which it sells with partner Eisai.
"We had very prosperous times in the more recent history of the company. And we have seen a... More
Biogen (BIIB) Tops Q2 EPS by 24c, Offers Guidance
July 25, 2023 7:02 AM EDTBiogen (NASDAQ: BIIB) reported Q2 EPS of $4.02, $0.24 better than the analyst estimate of $3.78. Revenue for the quarter came in at $2.46 billion versus the consensus estimate of $2.37 billion.
GUIDANCE:
Biogen sees FY2023 EPS of $15.00-$16.00, versus the consensus of $15.43.
Total revenue... MoreBiogen (BIIB) PT Lowered to $335 at UBS
July 24, 2023 9:22 AM EDTUBS analyst Colin Bristow lowered the price target on Biogen (NASDAQ: BIIB) to $335.00 (from $346.00) while maintaining a Buy rating.... More
